Pomerantz Law Firm Files Class Action Suit Against Fractyl Health, Inc. Over Securities Violations

Pomerantz Law Firm Launches Class Action Lawsuit Against Fractyl Health, Inc.

On September 24, 2026, Pomerantz LLP, a leading law firm known for its extensive practice in corporate and securities law, announced the filing of a class action lawsuit against Fractyl Health, Inc., also referenced by its NASDAQ ticker GUTS. The lawsuit has been registered in the United States District Court for the Southern District of New York, specifically under case number 26-cv-07167. It represents a collective of investors who purchased Fractyl securities during a designated class period from January 13, 2025 to January 29, 2026. The claim seeks to address alleged violations of federal securities laws and aims to secure damages for the affected parties.

The central focus of this class action revolves around the purported misinformation disseminated by Fractyl’s management about the efficacy of its flagship product, the Revita DMR System. Designed to treat type 2 diabetes and obesity, Revita is a significant part of Fractyl’s therapeutic portfolio. During the class period, Fractyl's leadership promoted Revita’s potential based on interim data from the REMAIN-1 clinical study, which was intended to evaluate the product’s long-term effects on weight maintenance following the cessation of GLP-1 receptor agonist therapies.

Despite claiming that interim results were